Accure Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  ACT-03 / Accure Therap
    Incubation of depression: stress and the extracellular matrix (Hall E1 [IN-PERSON, ONLINE]) -  Jul 23, 2022 - Abstract #ECNP2022ECNP_403;    
    Repeated injection was indeed able to prevent the initial stress-induced cognitive deficit. This suggests that ECM remodeling serves as a substrate in mediating stress-induced effects and that balanced ECM levels are vital for optimal memory processing.
  • ||||||||||  Trial completion date, Trial primary completion date:  ACUITY: OCS-05 in Patients With Acute Optic Neuritis (clinicaltrials.gov) -  Feb 24, 2022   
    P2,  N=36, Recruiting, 
    PREP modulation by ACT-02 improves PD neurodegeneration via multiple mechanisms in the Line 61 a-syn transgenic model, and therefore has potential therapeutic value for disease modifying treatment of PD. Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Aug 2021 --> Oct 2023
  • ||||||||||  ACT-01 / Accure Therap
    Journal:  Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. (Pubmed Central) -  Jun 29, 2020   
    In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases.
  • ||||||||||  ACT-01 / Accure Therap
    Trial completion:  BN201 SAD MAD Study in Healthy Subjects (clinicaltrials.gov) -  Apr 10, 2019   
    P1,  N=48, Completed, 
    It is also suggested that robustness not at the maximum level of translation is the selection target during evolution of WYMV RNA1. Recruiting --> Completed